Clinical and therapeutic profile of patients with hyperthyroidism in an outpatient endocrine clinic at a university hospital in southern Brazil
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2021.178114Keywords:
Hyperthyroidism, Graves’disease, Nodular goiterAbstract
Introduction: Hyperthyroidism results from the serum elevation of thyroid hormones, secondary to hyperfunction of the thyroid gland. The main causes are Graves' disease (DG) and Toxic Nodular Goiters (BNT). Objectives: Evaluate the clinical profile and therapeutic modalities applied in patients diagnosed with hyperthyroidism followed up at a University Hospital in Southern Brazil. Methods: Observational, cross-sectional and descriptive study, including patients diagnosed with hyperthyroidism by DG and BNT; epidemiological, clinical, laboratory and treatment data were collected. Results: Most patients were referred by primary care and had been using antithyroid drugs (DAT). The age variable obtained showed a statistically significant difference between the etiologies of DG and BNT; in both, there was a predominance of incidence in females. DG showed a higher frequency of signs and symptoms of thyrotoxicosis, while BNT showed more signs and symptoms of compression. There was remission of the disease in 23.2% of patients with DG treated with DAT; in 23.2% of the patients, low-dose methimazole was maintained for more than 36 months and in 16.1%, definitive treatment was performed. In BNT, definitive therapies were preferred, mainly thyroidectomy, in 27.5% of patients. Low doses of methimazole for more than 36 months were also used in BNT in 22.5% of patients. Conclusion: Hyperthyroidism is a heterogeneous disease, from initial clinic to therapy, among its most prevalent etiologies. There was a tendency to prioritize long-term drug therapies with low doses, both in DG and BNT.
Downloads
References
Kim M, Ladenson P. Tireoide. In: Goldman L, Ausinello DA. Goldman Cecil Medicina. 24 ed. Vol 2. Rio de Janeiro: Elsevier; 2014. p. 1665-80.
Ross DS, Burch HB, Cooper DS et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10):1343-421. doi: 10.1089/thy.2016.0229.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016; 388(10047):906-18. doi: http://dx.doi.org/10.1016/S0140-6736(16)00278-6
Graf H. Manuseio do bócio uninodular e multinodular tóxico. In Vilar L, editor. Endocrinologia clínica. 6 ed. Rio de Janeiro: Guanabara Koogan; 2016. p. 327-34.
Maia AL, Scheffel RS, Meyer ELS, et al. Consenso Brasileiro de diagnóstico e tratamento do hipertireoidismo: recomendações do Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia. Arq Bras Endocrinol Metab. 2013; 57(3):205-32. doi: 10.1590/S0004-27302013000300006.
Burch HB, Cooper DS. Antithyroid drug therapy: 70 years later. Eur J of Endocrinol. 2018; 195(5):261-274. doi: http://doi.org/10.1530/EJE-18-0678
Yeo CP, Khoo DH, Eng PH, Tan HK, Yo SL, Jacob E. Prevalence of gestational thyrotoxicosis in Asian women evaluated in the 8th to 14th weeks of pregnancy: correlations with total and free beta human chorionic gonadotrophin. Clin Endocrinol (Oxf). 2001; 55(3):391-8. doi: 10.1046/j.1365-2265.2001.01353.x.
Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008; 358(24): 2594-605. doi.: 10.1056/NEJMcp0801880.
Pontes AAN, Adan LF, Costa ADM, et al. Prevalência de Doenças da Tireoide em Uma Comunidade do Nordeste Brasileiro. Arq Bras Endocrinol Metab. 2002; 46(5):544-9. doi: http://dx.doi.org/10.1590/S0004-27302002000500008.
Doubleday AR, Sippel RS. Hyperthyroidism. Gland Surg. 2020; 9(1):124-135. doi:10.21037/gs.2019.11.01.
Brasil. Ministério da Saúde. Universidade Federal do Rio Grande do Sul. Protocolos de encaminhamento da atenção básica para atenção especializada v.1 - Endocrinologia e Nefrologia. Brasília: Ministério da Saúde; 2015. Disponível em http://bvsms.saude.gov.br/bvs/publicacoes/protocolos_atencao_basica_atencao_especializada_endocrinologia.pdf.
Hussain YS, Hookham JC, Allahabadia A, et al. Epidemiology, management and outcomes of Graves’disease – real life data. Endocrine. 2017; 56(3): 568-78. doi: 10.1007/s12020-017-1306-5.
Guevara-Linares X, Jasso-Huamán L, Ramírez-Vela RM, et al. Características clínicas, demográficas y perfil tiroideo de los pacientes hospitalizados por hipertiroidismo en un hospital general. Rev Med Hered. 2015; 26(3):141-6. Disponível em: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1018-130X2015000300002&lng=es.
Kahaly GJ, Bartalena L, Hegedus L, et al. 2018 European Thyroid Association Guideline for the Management of Grave’s Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-86. doi: 10.1159/000490384.
Sharma A, Stan MN. Thyrotoxicosis: Diagnosis and Management. Mayo Clin Proc. 2019; 94(6):1048-64. doi: https://doi.org/10.1016/j.mayocp.2018.10.011.
Yang H, Negishi K, Otahal P, Marwick TH. Clinical prediction of incident heart failure risk: a systematic review and meta-analysis. Open Heart. 2015; 2(1):e000222. doi: 10.1136/openhrt-2014-000222.
De Filippis EA, Sabet A, Sun MR, Garber JR. Pemberton's sign: explained nearly 70 years later. J Clin Endocrinol Metab. 2014; 99(6):1949-54. doi: 10.1210/jc.2013-4240.
Törring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine — a prospective, randomized study. J Clin Endocrinol Metab 1996; 81(8):2986-93. doi.: https://doi.org/10.1210/jcem.81.8.8768863.
Villagelin D, Romaldini JH, Santos BR, et al. Outcomes in Relapsed Graves’Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. Thyroid. 2015; 25(12):1282-90. doi: 10.1089/thy.2015.0195.
Azizi F, Ataie L, Hedayati M, et al. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. 2005; 152(5):695–701. doi: https://doi.org/10.1530/eje.1.01904.
Lauberg, P, Berman DC, Andersen S, et al. Sustained Controlo of Graves’ Hyperthyroidism During Long-Term Low-Dose Antithyroid Drug Therapy of Patients with Severe Graves’ Orbitopathy. Thyroid. 2011; 21(9):951-6. doi: 10.1089/thy.2011.0039.
Stumpf MAM, Schrut GCA, Ramthun M, Onuma S, Osternack HECG. Methimazole-induced agranulocytosis and sepsis: was thyroid storm present or just being mimicked? Acta Endocrinol (Buchar). 2019; 15(4):522-525. doi: 10.4183/aeb.2019.522.
Azizi F, Taikyar MA, Madreseh E, et al. Treatment of toxic multinodular goiter: Comparason of radiodine and long-term methimazole treatment. Thyroid. 2019; 29(5):625-30. doi: 10.1089/thy.2018.0397.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Rafael Antonio Parabocz1 Parabocz, Renata Soares Carvalho, Gianna Carla Alberti Schrut, Ana Claudia Garabeli Cavalli Kluthcovsky4 Kluthcovsky, Matheo Augusto Morandi Stumpf
This work is licensed under a Creative Commons Attribution 4.0 International License.
